<p><em>公司概述了针对使用点的执法技术的公共健康案例，并呼吁建立承认合规软件为烟草产品的监管框架</em></p>
<p>, /PRNewswire/ -- <strong>IKE Tech LLC</strong>（&#34;IKE Tech&#34;）是一家基于人工智能的合规基础设施公司，是 <strong>Ispire Technology Inc.</strong>（纳斯达克：ISPR）、Berify 和 Chemular Inc.之间的合资企业，参与了美国食品和药物管理局（FDA）烟草产品中心（CTP）的一次正式听证会。在会议上，IKE Tech 提出了使用点合规技术的公共健康案例，以防止青少年使用电子烟产品，介绍了其专利的人类身份令牌（HIT）技术，并概述了需要一个监管框架来将软件视为烟草产品。</p>
<p>此次会议使得与 CTP 直接互动，讨论了电子烟市场上两个最紧迫的执法挑战：使用点的未成年人接触和供应链中非法产品的泛滥。IKE Tech 概述了其合规基础设施平台，特点是使用点的生物识别年龄验证、基于区块链的产品认证和人工智能驱动的治理后台。这些共同构成了一种革命性的、以技术为驱动的解决方案，填补了现有控制措施无法解决的执法空白。</p>
<p>讨论的一个核心焦点是 IKE Tech 的立场，即嵌入或管理烟草产品的软件本身就是《烟草控制法》下的烟草产品，因此必须作为烟草产品进行监管。IKE Tech 强调，当前的 PMTA 框架是为静态物理产品设计的，无法充分考虑软件系统所需的持续更新和生命周期管理。IKE Tech 还提出了 CTP 可以解决这一差距的潜在途径，借鉴了该机构在其他地方已建立的监管方法。</p>
<p>&#34;与 CTP 的这次互动明确表明，今天的主要执法挑战——未成年人接触和非法产品——不能仅在销售点解决，&#34; IKE Tech 董事会成员 Steven Pryzbyla 表示。&#34;使用点技术和软件驱动的系统已成为有效合规的必要条件。因此，监管框架需要跟上并与之共同发展。我们对这一对话感到鼓舞，并期待继续与 FDA 合作，寻找前进的道路。&#34;</p>
<p>&#34;我们相信合规的未来必须直接融入产品体验中，&#34; Ispire Technology Inc.的联合首席执行官 Michael Wang 表示。&#34;通过我们的合资企业 IKE Tech，我们正在开发代表行业在合规方法上根本转变的技术，将年龄验证、认证和实时设备治理直接集成到专有软件层中。通过使用技术驱动的解决方案从被动执法转向主动执法，我们旨在解决使用点的未成年人接触和非法贸易的根本原因。这次与 FDA 的互动是建立一个承认软件和连接系统在促进公共健康方面所发挥作用的监管框架的重要一步，同时支持一个负责任、可持续的市场。&#34;</p>
<p>此次互动建立在更广泛的监管顺风上。2026 年 3 月，FDA 关于调味电子烟的草案指南明确指出，设备访问限制（DAR）可能是对电子烟产品进行适合公共健康保护（APPH）评估的重要因素——这是 IKE Tech 的技术旨在满足的框架。</p>
<p>该合资企业提交了首个独立组件 PMTA，针对一种可互操作的、基于区块链的使用点年龄验证技术，该申请于 2025 年 6 月被 FDA 接受。作为 PMTA 的一部分提交的多中心人因验证研究也证明在防止未成年人设备激活方面具有 100% 的有效性，91% 的成年参与者评价该应用程序极其或非常易于使用。</p>
<p><strong>关于 IKE Tech LLC</strong></p>
<p>IKE Tech LLC 是一家基于人工智能的合规基础设施公司，是 Ispire Technology Inc.（纳斯达克：ISPR）、Touch Point Worldwide Inc.（即 Berify）和 Chemular Inc.之间的合资企业，成立于 2024 年。IKE 构建并运营连接设备、包装和身份的基础设施层，形成一个为全球制造商、品牌、零售商和监管机构服务的单一模块化平台。有关更多信息，请访问 www.iketech.com。</p>
<p><strong>关于 Ispire Technology Inc.</strong></p>
<p>Ispire 从事品牌电子烟和大麻蒸汽产品的研究与开发、设计、商业化、销售、市场营销和分销。公司的运营子公司在全球拥有或许可超过 400 项专利。Ispire 的品牌电子烟产品以 Aspire 名称进行市场营销，并在全球（美国、中华人民共和国和俄罗斯除外）通过其全球分销网络销售。该公司还与全球电子烟品牌和零售商建立了原始设计制造（ODM）关系。公司的大麻产品主要以 Ispire 品牌名称在 ODM 基础上向其他大麻蒸汽公司进行市场营销。Ispire 在美国、欧洲和南非销售其大麻蒸汽硬件，并最近开始在加拿大和拉丁美洲进行市场营销活动和客户互动。有关更多信息，请访问 www.ispiretechnology.com 或在 Instagram、LinkedIn、Twitter 和 YouTube 上关注 Ispire。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据《1933 年证券法》第 27A 条（经修订）和《1934 年证券交易法》第 21E 条（经修订）以及《1995 年私人证券诉讼改革法案》（经修订）所定义的前瞻性陈述，这些陈述旨在受到这些条款所创造的安全港的保护。前瞻性陈述基于某些假设，并描述了公司的未来计划、战略和预期，通常可以通过使用诸如 “相信”、“期望”、“可能”、“将”、“应该”、“会”、“能够”、“寻求”、“打算”、“计划”、“目标”、“项目”、“估计”、“预期”、“战略”、“未来”、“可能” 等前瞻性术语来识别，尽管并非所有前瞻性陈述都包含这些识别词。除历史事实陈述外，本新闻稿中关于公司战略、前景、财务状况、运营、成本、计划和目标的所有陈述均为前瞻性陈述。可能导致公司实际结果和财务状况与前瞻性陈述中所指示的结果有重大差异的重要因素。这些前瞻性陈述包括但不限于以下风险和不确定性：公司是否能够成功重新进入美国 ENDS 市场；公司提交的任何 PMTA 的批准或拒绝；公司是否能够成功进一步扩展到非洲市场；公司与 Touch Point Worldwide Inc.（以 Berify 和 Chemular Inc.名义运营）的合资企业（“合资企业”）是否能够成功实现其当前设想的目标，或以不同条款实现目标；合资企业在电子烟技术领域创新的能力或开发尼古丁蒸汽设备的年龄限制或年龄验证技术的能力；公司及时收回应收账款的能力；公司的商业战略；公司向 Ispire ONE™进行市场营销的能力；Ispire ONE™在实现其目标方面的成功；客户从 Ispire ONE™中获得预期利益的能力以及其产品在市场上的成功；Ispire ONE™被证明是安全的；以及在 Ispire 截至 2025 年 6 月 30 日的年度报告的 “风险因素”、“管理层对财务状况和经营成果的讨论与分析”、“前瞻性陈述的警示说明” 以及 Ispire 向 SEC 提交的任何后续文件中描述的风险和不确定性。您不应将前瞻性陈述视为对未来事件的预测。本新闻稿中所作的前瞻性陈述仅与声明作出之日的事件或信息相关。我们没有义务更新或修订任何前瞻性陈述，无论是由于新信息、未来事件还是其他原因，声明作出之日后，或反映意外事件的发生，除非适用法律要求。您应理解，实际未来结果可能与我们的预期有重大不同。</p>
<p>来源：IKE Tech LLC</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA5Jk5ld3NJdGVtSWQ9TlkzMDI4OSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDkwNzAwUFJfTkVXU19VU1BSX19fX19OWTMwMjg5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA5Jk5ld3NJdGVtSWQ9TlkzMDI4OSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDkwNzAwUFJfTkVXU19VU1BSX19fX19OWTMwMjg5"/></p>

ISPR

<p>IKE Tech LLC 是一家与 Ispire Technology Inc.合作的合资企业，已与 FDA 进行接洽，讨论针对电子烟产品的合规技术。他们展示了人类身份令牌技术，并强调需要一个将软件视为烟草产品的监管框架。讨论的重点是通过创新的合规解决方案来解决未成年人获取和非法产品的问题，包括生物识别年龄验证和区块链认证。IKE Tech 旨在从被动执法转向主动执法，倡导与技术发展相适应的法规，以提升公共健康和市场可持续性</p>

<p><em>Companies outline public health case for point-of-use enforcement technologies and call for regulatory framework recognizing compliance software as a tobacco product</em></p>
<div class="lb-trans"><p><em>公司概述了针对使用点的执法技术的公共健康案例，并呼吁建立承认合规软件为烟草产品的监管框架</em></p>
</div><p>, /PRNewswire/ -- <strong>IKE Tech LLC</strong> (&#34;IKE Tech&#34;), an AI-powered compliance infrastructure company and joint venture among <strong>Ispire Technology Inc.</strong> (NASDAQ: ISPR), Berify, and Chemular Inc., participated in a formal listening session with the U.S. Food and Drug Administration's (FDA) Center for Tobacco Products (CTP). During the session, IKE Tech presented the public health case for point-of-use compliance technology to prevent youth usage of ENDS products, its patented Human Identity Token (HIT) technology, and outlined the need for a regulatory framework addressing software as a tobacco product.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- <strong>IKE Tech LLC</strong>（&#34;IKE Tech&#34;）是一家基于人工智能的合规基础设施公司，是 <strong>Ispire Technology Inc.</strong>（纳斯达克：ISPR）、Berify 和 Chemular Inc.之间的合资企业，参与了美国食品和药物管理局（FDA）烟草产品中心（CTP）的一次正式听证会。在会议上，IKE Tech 提出了使用点合规技术的公共健康案例，以防止青少年使用电子烟产品，介绍了其专利的人类身份令牌（HIT）技术，并概述了需要一个监管框架来将软件视为烟草产品。</p>
</div><p>The session enabled direct engagement with CTP on two of the most pressing enforcement challenges in the ENDS market: underage access at the point of use and the proliferation of illicit products within the supply chain. IKE Tech outlined its compliance infrastructure platform, featuring biometric age-gating at the point of use, blockchain-based product authentication, and an AI-powered governance backend. Together, these represent a revolutionary, technology-driven solution to enforcement gaps that existing controls cannot address.</p>
<div class="lb-trans"><p>此次会议使得与 CTP 直接互动，讨论了电子烟市场上两个最紧迫的执法挑战：使用点的未成年人接触和供应链中非法产品的泛滥。IKE Tech 概述了其合规基础设施平台，特点是使用点的生物识别年龄验证、基于区块链的产品认证和人工智能驱动的治理后台。这些共同构成了一种革命性的、以技术为驱动的解决方案，填补了现有控制措施无法解决的执法空白。</p>
</div><p>A central focus of the discussion was IKE Tech's position that software embedded in, or governing, a tobacco product is itself a tobacco product under the Tobacco Control Act, and therefore must be regulated as such. IKE Tech emphasized that the current PMTA framework, which is designed for static physical products, does not adequately account for the continuous updates and lifecycle management required for software-based systems. IKE Tech also presented potential pathways for CTP to address this gap, drawing on regulatory approaches already established elsewhere within the agency.</p>
<div class="lb-trans"><p>讨论的一个核心焦点是 IKE Tech 的立场，即嵌入或管理烟草产品的软件本身就是《烟草控制法》下的烟草产品，因此必须作为烟草产品进行监管。IKE Tech 强调，当前的 PMTA 框架是为静态物理产品设计的，无法充分考虑软件系统所需的持续更新和生命周期管理。IKE Tech 还提出了 CTP 可以解决这一差距的潜在途径，借鉴了该机构在其他地方已建立的监管方法。</p>
</div><p>&#34;What this engagement with CTP made clear is that today's primary enforcement challenges – underage access and illicit products – cannot be solved at the point of sale alone,&#34; said Steven Pryzbyla, board member of IKE Tech. &#34;Point-of-use technologies and software-driven systems have become essential to effective compliance. As a result, the regulatory framework needs to catch up and evolve alongside it. We're encouraged by the dialogue and look forward to continuing to work with FDA on a path forward.&#34;</p>
<div class="lb-trans"><p>&#34;与 CTP 的这次互动明确表明，今天的主要执法挑战——未成年人接触和非法产品——不能仅在销售点解决，&#34; IKE Tech 董事会成员 Steven Pryzbyla 表示。&#34;使用点技术和软件驱动的系统已成为有效合规的必要条件。因此，监管框架需要跟上并与之共同发展。我们对这一对话感到鼓舞，并期待继续与 FDA 合作，寻找前进的道路。&#34;</p>
</div><p>&#34;We believe the future of compliance must be built directly into the product experience,&#34; said Michael Wang, co-CEO of Ispire Technology Inc. &#34;Through our joint venture IKE Tech, we are developing technologies that represent a fundamental shift in how the industry approaches compliance, integrating age-gating, authentication, and real-time device governance directly into a proprietary software layer. By moving from reactive to proactive enforcement using technology-driven solutions, we aim to address the root causes of underage access and illicit trade at the point of use. This engagement with FDA is an important step toward establishing a regulatory framework that recognizes the role software and connected systems will play in advancing public health while supporting a responsible, sustainable market.&#34;</p>
<div class="lb-trans"><p>&#34;我们相信合规的未来必须直接融入产品体验中，&#34; Ispire Technology Inc.的联合首席执行官 Michael Wang 表示。&#34;通过我们的合资企业 IKE Tech，我们正在开发代表行业在合规方法上根本转变的技术，将年龄验证、认证和实时设备治理直接集成到专有软件层中。通过使用技术驱动的解决方案从被动执法转向主动执法，我们旨在解决使用点的未成年人接触和非法贸易的根本原因。这次与 FDA 的互动是建立一个承认软件和连接系统在促进公共健康方面所发挥作用的监管框架的重要一步，同时支持一个负责任、可持续的市场。&#34;</p>
</div><p>The engagement builds on a broader regulatory tailwind. In March 2026, FDA's draft guidance on flavored ENDS explicitly identified Device Access Restrictions (DAR) as a potentially significant factor in appropriate-for-the-protection-of-public-health (APPH) determinations for ENDS products—a framework IKE Tech's technology is designed to meet.</p>
<div class="lb-trans"><p>此次互动建立在更广泛的监管顺风上。2026 年 3 月，FDA 关于调味电子烟的草案指南明确指出，设备访问限制（DAR）可能是对电子烟产品进行适合公共健康保护（APPH）评估的重要因素——这是 IKE Tech 的技术旨在满足的框架。</p>
</div><p>The joint venture submitted the first standalone component PMTA of its kind for an interoperable, blockchain-based, point-of-use age-gating technology, which was accepted by the FDA in June 2025. A multi-center Human Factors Validation Study, submitted as part of the PMTA, also demonstrated 100% effectiveness in preventing underage device activation, with 91% of adult participants rating the application extremely or very easy to use.</p>
<div class="lb-trans"><p>该合资企业提交了首个独立组件 PMTA，针对一种可互操作的、基于区块链的使用点年龄验证技术，该申请于 2025 年 6 月被 FDA 接受。作为 PMTA 的一部分提交的多中心人因验证研究也证明在防止未成年人设备激活方面具有 100% 的有效性，91% 的成年参与者评价该应用程序极其或非常易于使用。</p>
</div><p><strong>About IKE Tech LLC</strong></p>
<div class="lb-trans"><p><strong>关于 IKE Tech LLC</strong></p>
</div><p>IKE Tech LLC is an AI-powered compliance infrastructure company and joint venture among Ispire Technology Inc. (NASDAQ: ISPR), Touch Point Worldwide Inc. d/b/a Berify, and Chemular Inc., founded in 2024. IKE builds and operates the infrastructure layer that connects devices, packaging, and identity into a single, modular platform serving manufacturers, brands, retailers, and regulators globally. For more information, visit www.iketech.com.</p>
<div class="lb-trans"><p>IKE Tech LLC 是一家基于人工智能的合规基础设施公司，是 Ispire Technology Inc.（纳斯达克：ISPR）、Touch Point Worldwide Inc.（即 Berify）和 Chemular Inc.之间的合资企业，成立于 2024 年。IKE 构建并运营连接设备、包装和身份的基础设施层，形成一个为全球制造商、品牌、零售商和监管机构服务的单一模块化平台。有关更多信息，请访问 www.iketech.com。</p>
</div><p><strong>About Ispire Technology Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Ispire Technology Inc.</strong></p>
</div><p>Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 400 patents worldwide. Ispire's branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company's cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.</p>
<div class="lb-trans"><p>Ispire 从事品牌电子烟和大麻蒸汽产品的研究与开发、设计、商业化、销售、市场营销和分销。公司的运营子公司在全球拥有或许可超过 400 项专利。Ispire 的品牌电子烟产品以 Aspire 名称进行市场营销，并在全球（美国、中华人民共和国和俄罗斯除外）通过其全球分销网络销售。该公司还与全球电子烟品牌和零售商建立了原始设计制造（ODM）关系。公司的大麻产品主要以 Ispire 品牌名称在 ODM 基础上向其他大麻蒸汽公司进行市场营销。Ispire 在美国、欧洲和南非销售其大麻蒸汽硬件，并最近开始在加拿大和拉丁美洲进行市场营销活动和客户互动。有关更多信息，请访问 www.ispiretechnology.com 或在 Instagram、LinkedIn、Twitter 和 YouTube 上关注 Ispire。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (&#34;Securities Act&#34;) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as &#34;believe,&#34; &#34;expect,&#34; &#34;may,&#34; &#34;will,&#34; &#34;should,&#34; &#34;would,&#34; &#34;could,&#34; &#34;seek,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;goal,&#34; &#34;project,&#34; &#34;estimate,&#34; &#34;anticipate,&#34; &#34;strategy,&#34; &#34;future,&#34; &#34;likely&#34; or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company's joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the &#34;Joint Venture&#34;) may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture's ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company's ability to collect its accounts receivable in a timely manner; the Company's business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™'s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in &#34;Risk Factors,&#34; &#34;Management's Discussion and Analysis of Financial Condition and Results of Operations,&#34; &#34;Cautionary Note on Forward-Looking Statements&#34; and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.</p>
<div class="lb-trans"><p>本新闻稿包含根据《1933 年证券法》第 27A 条（经修订）和《1934 年证券交易法》第 21E 条（经修订）以及《1995 年私人证券诉讼改革法案》（经修订）所定义的前瞻性陈述，这些陈述旨在受到这些条款所创造的安全港的保护。前瞻性陈述基于某些假设，并描述了公司的未来计划、战略和预期，通常可以通过使用诸如 “相信”、“期望”、“可能”、“将”、“应该”、“会”、“能够”、“寻求”、“打算”、“计划”、“目标”、“项目”、“估计”、“预期”、“战略”、“未来”、“可能” 等前瞻性术语来识别，尽管并非所有前瞻性陈述都包含这些识别词。除历史事实陈述外，本新闻稿中关于公司战略、前景、财务状况、运营、成本、计划和目标的所有陈述均为前瞻性陈述。可能导致公司实际结果和财务状况与前瞻性陈述中所指示的结果有重大差异的重要因素。这些前瞻性陈述包括但不限于以下风险和不确定性：公司是否能够成功重新进入美国 ENDS 市场；公司提交的任何 PMTA 的批准或拒绝；公司是否能够成功进一步扩展到非洲市场；公司与 Touch Point Worldwide Inc.（以 Berify 和 Chemular Inc.名义运营）的合资企业（“合资企业”）是否能够成功实现其当前设想的目标，或以不同条款实现目标；合资企业在电子烟技术领域创新的能力或开发尼古丁蒸汽设备的年龄限制或年龄验证技术的能力；公司及时收回应收账款的能力；公司的商业战略；公司向 Ispire ONE™进行市场营销的能力；Ispire ONE™在实现其目标方面的成功；客户从 Ispire ONE™中获得预期利益的能力以及其产品在市场上的成功；Ispire ONE™被证明是安全的；以及在 Ispire 截至 2025 年 6 月 30 日的年度报告的 “风险因素”、“管理层对财务状况和经营成果的讨论与分析”、“前瞻性陈述的警示说明” 以及 Ispire 向 SEC 提交的任何后续文件中描述的风险和不确定性。您不应将前瞻性陈述视为对未来事件的预测。本新闻稿中所作的前瞻性陈述仅与声明作出之日的事件或信息相关。我们没有义务更新或修订任何前瞻性陈述，无论是由于新信息、未来事件还是其他原因，声明作出之日后，或反映意外事件的发生，除非适用法律要求。您应理解，实际未来结果可能与我们的预期有重大不同。</p>
</div><p>SOURCE IKE Tech LLC</p>
<div class="lb-trans"><p>来源：IKE Tech LLC</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA5Jk5ld3NJdGVtSWQ9TlkzMDI4OSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDkwNzAwUFJfTkVXU19VU1BSX19fX19OWTMwMjg5" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY30289&amp;Transmission_Id=202604090700PR_NEWS_USPR_____NY30289&amp;DateId=20260409"/></p>

07:00 ETIKE 科技与 FDA 就下一代电子尼古丁传送系统（ENDS）的合规基础设施展开接洽